Mitogen-Activated Protein Kinase Inhibitors Improve Heart Function and Prevent Fibrosis in Cardiomyopathy Caused by Mutation in Lamin A/C Gene

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Circulation

• Publication date

  2011-01-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.110.970673PMID 21173351PMCID PMC3061281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.

  2010cited by this paper
• Therapeutic targeting of signaling pathways in muscular dystrophy

  2010cited by this paper
• Improvement of left ventricular dysfunction and of survival prognosis of dilated cardiomyopathy by administration of calcium sensitizer SCH00013 in a mouse model.

  2010cited by this paper
• Vascular formation of nitrite after exercise is abolished in patients with cardiovascular risk factors and coronary artery disease.

  2010cited by this paper
• Morphological Analysis of 13 LMNA Variants Identified in a Cohort of 324 Unrelated Patients With Idiopathic or Familial Dilated Cardiomyopathy

  2010cited by this paper
• Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene.

  2010cited by this paper
• Effects of Mechanical Stress and Carvedilol in Lamin A/C–Deficient Dilated Cardiomyopathy

  2010cited by this paper
• Laminopathies and the long strange trip from basic cell biology to therapy.

  2009cited by this paper
• Long-term outcome and risk stratification in dilated cardiolaminopathies.

  2008cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• Inhibition of extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins.

  2008cited by this paper
• Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.

  2007cited by this paper
• Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy.

  2007cited by this paper
• High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics.

  2007cited by this paper
• Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

  2007cited by this paper
• Mid-myocardial fibrosis by cardiac magnetic resonance in patients with lamin A/C cardiomyopathy: possible substrate for diastolic dysfunction.

  2007cited by this paper
• Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C gene.

  2007cited by this paper
• The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions

  2006cited by this paper
• Cardiomyopathy, familial dilated

  2006cited by this paper
• A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

  2005cited by this paper
• Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies.

  2005cited by this paper
• Simple Clinical Criteria to Determine the Prognosis of Heart Failure

  2005cited by this paper
• The cardiac fibroblast: therapeutic target in myocardial remodeling and failure.

  2005cited by this paper
• Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients

  2005cited by this paper
• Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: altered expression of apoptotic and cytoskeletal genes.

  2004cited by this paper
• Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?

  2004cited by this paper
• Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme

  2004cited by this paper
• Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice.

  2004cited by this paper
• Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.

  2003cited by this paper
• Pharmacological strategies for muscular dystrophy

  2003cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

  2003cited by this paper
• Selection of endpoints for heart failure clinical trials

  2003cited by this paper
• Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes

  2003cited by this paper
• Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure.

  2002cited by this paper
• Angiotensin II and trials of cardiovascular outcomes.

  2002cited by this paper
• Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients

  2002cited by this paper
• Models of dilated cardiomyopathy in the mouse and the hamster.

  2000cited by this paper
• Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B).

  2000cited by this paper
• Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease

  2000cited by this paper
• Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement.

  2000cited by this paper
• Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)

  2000cited by this paper
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

  2000cited by this paper
• Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy

  1999cited by this paper
• Molecular mechanisms of myocardial remodeling.

  1999cited by this paper
• Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.

  1999cited by this paper
• Molecular Mechanisms of Myocardial Remodeling

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Altered expression of atrial natriuretic peptide and contractile protein genes in hypertrophied ventricle of JVS mice with systemic carnitine deficiency.

  1997cited by this paper
• End‐Systolic Volume and Long‐term Survival After Coronary Artery Bypass Graft Surgery in Patients With Impaired Left Ventricular Function

  1994cited by this paper
• Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene.

  1992cited by this paper
• Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

  1987cited by this paper

• Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias.

  2026cites this paper
• Genetic Cardiomyopathies: An Overview of the Main Associated Pathogenic Mutations

  2025cites this paper
• Microtubule forces drive nuclear damage in LMNA cardiomyopathy

  2025cites this paper
• Changes in Chromatin Organisation and Mechanotransduction Mediated by Mutant Lamins in Laminopathies.

  2025cites this paper
• Deregulated nutrient response in ttntv cardiomyopathy can be repaired via Erk inhibition for cardioprotective effects.

  2025cites this paper
• Cardiomiopatias Genéticas: Uma Visão Geral das Principais Mutações Patogênicas Associadas

  2025cites this paper
• LMNA-related cardiomyopathy: From molecular pathology to cardiac gene therapy

  2025cites this paper
• Perinuclear organelle trauma at the nexus of cardiomyopathy pathogenesis arising from loss of function LMNA mutation

  2025cites this paper
• SIRT1 Ameliorates Lamin A/C Deficiency-Induced Cardiac Dysfunction by Promoting Mitochondrial Bioenergetics

  2024cites this paper
• Risk Assessment and Personalized Treatment Options in Inherited Dilated Cardiomyopathies: A Narrative Review

  2024cites this paper
• Sulfenylation of ERK1/2: A novel mechanism for SO2-mediated inhibition of cardiac fibroblast proliferation

  2024cites this paper
• Pirfenidone Prevents Heart Fibrosis during Chronic Chagas Disease Cardiomyopathy

  2024cites this paper
• mTOR Inhibition Prolongs Survival and Has Beneficial Effects on Heart Function After Onset of Lamin A/C Gene Mutation Cardiomyopathy in Mice

  2024cites this paper
• From gene to mechanics: a comprehensive insight into the mechanobiology of LMNA mutations in cardiomyopathy

  2024cites this paper
• Targeting MAPK-ERK/JNK pathway: A potential intervention mechanism of myocardial fibrosis in heart failure.

  2024cites this paper
• The structure and function of lamin A/C: Special focus on cardiomyopathy and therapeutic interventions.

  2024cites this paper
• Microtubule forces drive nuclear damage in LMNA cardiomyopathy

  2024cites this paper
• Cardiomyopathy: pathogenesis and therapeutic interventions

  2024cites this paper
• The Pathogenic Mechanisms of and Novel Therapies for Lamin A/C-Related Dilated Cardiomyopathy Based on Patient-Specific Pluripotent Stem Cell Platforms and Animal Models

  2024cites this paper
• InterLINCing Chromatin Organization and Mechanobiology in Laminopathies

  2023cites this paper
• Emerging Targeted Therapies for Inherited Cardiomyopathies and Arrhythmias.

  2023cites this paper
• An alpha-helix variant p.Arg156Pro in LMNA as a cause of hereditary dilated cardiomyopathy: genetics and bioinfomatics exploration

  2023cites this paper
• Pervasive nuclear envelope ruptures precede ECM signaling and disease onset without activating cGAS-STING in Lamin-cardiomyopathy mice

  2023cites this paper
• Emerin deficiency does not exacerbate cardiomyopathy in a murine model of Emery–Dreifuss muscular dystrophy caused by an LMNA gene mutation

  2023cites this paper
• Precision therapy in dilated cardiomyopathy: Pipedream or paradigm shift?

  2023cites this paper
• Comprehensive review on gene mutations contributing to dilated cardiomyopathy

  2023cites this paper
• Transcriptome studies of inherited dilated cardiomyopathies

  2023cites this paper
• Epigenetics in LMNA-Related Cardiomyopathy

  2023cites this paper
• Nesprin-1: novel regulator of striated muscle nuclear positioning and mechanotransduction

  2023cites this paper
• Effective use of genetically-encoded optical biosensors for profiling signalling signatures in iPSC-CMs derived from idiopathic dilated cardiomyopathy patients

  2022cites this paper
• Actin-microtubule cytoskeletal interplay mediated by MRTF-A/SRF signaling promotes dilated cardiomyopathy caused by LMNA mutations

  2022cites this paper
• Aberrant chromatin organization at the nexus of laminopathy disease pathways

  2022cites this paper
• The addition of genetic testing and cardiovascular magnetic resonance to routine clinical data for stratification of etiology in dilated cardiomyopathy

  2022cites this paper
• Rare and potential pathogenic mutations of LMNA and LAMA4 associated with familial arrhythmogenic right ventricular cardiomyopathy/dysplasia with right ventricular heart failure, cerebral thromboembolism and hereditary electrocardiogram abnormality

  2022cites this paper
• Protein kinases in cardiovascular diseases

  2022cites this paper
• Nuclear Lamins: Key Proteins for Embryonic Development

  2022cites this paper
• Genetic predisposition study of heart failure and its association with cardiomyopathy

  2022cites this paper
• Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes.

  2021cites this paper
• Integrated analysis reveals the alterations that LMNA interacts with euchromatin in LMNA mutation-associated dilated cardiomyopathy

  2021cites this paper
• Preclinical Advances of Therapies for Laminopathies

  2021cites this paper
• Phenotypic Variability in iPSC-Induced Cardiomyocytes and Cardiac Fibroblasts Carrying Diverse LMNA Mutations

  2021cites this paper
• Phosphorylation of Lamin A/C at serine 22 modulates Nav1.5 function

  2021cites this paper
• A CRISPR/Cas9 zebrafish lamin A/C mutant model of muscular laminopathy

  2021cites this paper
• Disrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy

  2021cites this paper
• THE NUCLEUS: mechanosensing in cardiac disease.

  2021cites this paper
• Cardiomyocyte Proliferative Capacity Is Restricted in Mice With Lmna Mutation

  2021cites this paper
• Myocardial Fibrosis in Dilated Cardiomyopathy: Moving From Stratifying Risk to Improving Outcomes.

  2021cites this paper
• Contemporary and Future Approaches to Precision Medicine in Inherited Cardiomyopathies: JACC Focus Seminar 3/5.

  2021cites this paper
• Role of Cdkn2a in the Emery–Dreifuss Muscular Dystrophy Cardiac Phenotype

  2021cites this paper
• Transcriptome signature of ventricular arrhythmia in dilated cardiomyopathy reveals increased fibrosis and activated TP53.

  2020cites this paper
• Editorial commentary: Myocardial fibrosis in genetic cardiomyopathies: A cause of dysfunction, or simply an epiphenomenon?

  2020cites this paper
• Ryanodine receptor remodeling in cardiomyopathy and muscular dystrophy caused by lamin A/C gene mutation.

  2020cites this paper
• Protein Kinase C Alpha Cellular Distribution, Activity, and Proximity with Lamin A/C in Striated Muscle Laminopathies

  2020cites this paper
• MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water

  2020cites this paper
• PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice

  2020cites this paper
• Nuclear mechanotransduction in stem cells.

  2020cites this paper
• Genotype‐phenotype analysis of LMNA‐related diseases predicts phenotype‐selective alterations in lamin phosphorylation

  2020cites this paper
• The role of the cell nucleus in mechanotransduction.

  2020cites this paper
• RNA Sequence Analyses throughout the Course of Mouse Cardiac Laminopathy Identify Differentially Expressed Genes for Cell Cycle Control and Mitochondrial Function

  2020cites this paper
• Myonuclear alterations in ageing syndromes

  2019cites this paper
• Lamin A/C Cardiomyopathy: Implications for Treatment

  2019cites this paper
• Targeting MRTF/SRF in CAP2-dependent dilated cardiomyopathy delays disease onset.

  2019cites this paper
• Computational Model Predicts Paracrine and Intracellular Drivers of Fibroblast Phenotype After Myocardial Infarction

  2019cites this paper
• Precision Medicine in the Management of Dilated Cardiomyopathy: JACC State-of-the-Art Review.

  2019cites this paper
• Cellular and Animal Models of Striated Muscle Laminopathies

  2019cites this paper
• Alteration of performance in a mouse model of Emery-Dreifuss muscular dystrophy caused by A-type lamins gene mutation.

  2019cites this paper
• Ablation of SUN2-containing LINC complexes drives cardiac hypertrophy without interstitial fibrosis

  2019influential citation
• Deficiency of emerin contributes differently to the pathogenesis of skeletal and cardiac muscles in LmnaH222P/H222P mutant mice

  2019cites this paper
• Role of Lamin A/C Gene Mutations in the Signaling Defects Leading to Cardiomyopathies

  2018cites this paper
• Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-β signaling results in variable activation of human dermal fibroblasts

  2018cites this paper
• Vangl2 is essential for myocardial remodeling activated by Wnt/JNK signaling

  2018cites this paper
• Rutaecarpine prevents hypertensive cardiac hypertrophy involving the inhibition of Nox4‐ROS‐ADAM17 pathway

  2018cites this paper
• Linker of nucleoskeleton and cytoskeleton complex proteins in cardiomyopathy

  2018cites this paper
• Mechanotransduction, nuclear architecture and epigenetics in Emery Dreifuss Muscular Dystrophy: tous pour un, un pour tous

  2018cites this paper
• Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival

  2018cites this paper
• Fibrotic Signaling in Cardiomyopathies

  2018cites this paper
• Cofilin-1 phosphorylation catalyzed by ERK1/2 alters cardiac actin dynamics in dilated cardiomyopathy caused by lamin A/C gene mutation

  2018cites this paper
• Intermediate filaments in cardiomyopathy

  2018cites this paper
• Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins

  2018cites this paper
• Endoplasmic reticulum stress impairs cardiomyocyte contractility through JNK-dependent upregulation of BNIP3.

  2018cites this paper
• Genetic mutation of familial dilated cardiomyopathy based on next-generation semiconductor sequencing

  2018cites this paper
• MAPK signaling pathways and HDAC3 activity are disrupted during differentiation of emerin-null myogenic progenitor cells

  2017influential citation
• Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload.

  2017cites this paper
• Cell signaling abnormalities in cardiomyopathy caused by lamin A/C gene mutations.

  2017cites this paper
• Functional Characterization of a Novel Truncating Mutation in Lamin A/C Gene in a Family with a Severe Cardiomyopathy with Conduction Defects

  2017cites this paper
• Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis

  2017cites this paper
• Current insights into LMNA cardiomyopathies: Existing models and missing LINCs

  2017cites this paper
• Hepatocyte-Specific Deletion of Mouse Lamin A/C Leads to Male-Selective Steatohepatitis

  2017cites this paper
• Lamin A/C Cardiomyopathies: Current Understanding and Novel Treatment Strategies

  2017cites this paper
• Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy

  2017cites this paper
• Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation.

  2017cites this paper
• Dilated Cardiomyopathy: Genetic Determinants and Mechanisms

  2017cites this paper
• Lipid-induced cardiovascular diseases

  2017cites this paper
• Idiopathic Dilated Cardiomyopathy: Molecular Basis and Distilling Complexity to Advance

  2017cites this paper
• Diseases of the Nuclear Membrane

  2017cites this paper
• Recent Advances in Understanding and Managing Cardiomyopathy

  2017cites this paper
• Decreased WNT/&bgr;-catenin signalling contributes to the pathogenesis of dilated cardiomyopathy caused by mutations in the lamin a/C gene

  2017cites this paper
• Genetic Variations Leading to Familial Dilated Cardiomyopathy

  2016cites this paper
• Recent advances in animal and human pluripotent stem cell modeling of cardiac laminopathy

  2016cites this paper
• Targeting Mitogen-Activated Protein Kinase Signaling in Mouse Models of Cardiomyopathy Caused by Lamin A/C Gene Mutations.

  2016cites this paper